medigraphic.com
Instituto Nacional de Ciencias Médicas y Nutrición Salvador Zubirán

2006, Number 4

<< Back Next >>

Rev Invest Clin 2006; 58 (4)

Role of peroxynitrite anion in different diseases

Chirino YI, Orozco-Ibarra M, Pedraza-Chaverrí J

Language: Spanish
References: 58
Page: 350-358
PDF size: 106.49 Kb.


ABSTRACT

Peroxynitrite (ONOO¯) is a reactive nitrogen specie produced by the reaction between nitric oxide (NO•) and superoxide anion (O2•¯). NO• is produced by nitric oxide synthase (NOS) and O2•¯ is formed by the addition of an electron to O2 in enzymatic as well as nonenzymatic way. NADPH oxidase and xanthine oxidase are some of the enzymes involved in O2•¯ formation. ONOO¯ is an oxidant specie which is able to modify a great number of biomolecules such as aminoacids, proteins, enzymes and cofactors. ONOO¯ is able to induce nitration leading to the formation of 3-nytrotyrosine. This change has been widely studied, and although it is not only produced by ONOO¯, but also by other reactive nitrogen species, it has been accepted like footprint of ONOO¯. The excessive production of reactive nitrogen species is known as nitrosative stress that is able to induce structural damage leading to the loss of cell function. Furthermore, synthetic metalloporphyrins that metabolize ONOO¯ in a specific way are being used to determine if ONOO¯ is involved in different diseases, such as Alzheimer, Huntington, diabetes, hypertension, arthritis, colitis, cardiac and renal complications. Finally, these metalloporphyrins may be of potential therapeutic value in diseases related to ONOO¯ production.


REFERENCES

  1. Halliwell B. Oxidants and human disease: some new concepts. FASEB J 1987; 1: 358-64.

  2. Furchgott RF, Zawadzki JV. The obligatory role of endothelial cells in the relaxation of arterial smooth muscle by acetylcholine. Nature 1980, 288; 373-6.

  3. Vertuani S, Angusti A, Manfredini S. The antioxidants and pro-antioxidants network: an overview. Curr Pharm Des 2004; 10: 1677-94.

  4. Kone BC. Nitric oxide synthesis in the kidney: isoforms, biosynthesis, and functions in health. Semin Nephrol 2004; 24: 299-315.

  5. Symons MC. Cis- and trans-conformations for peroxynitrite anions. J Inorg Biochem 2000; 78: 299-301.

  6. Motterlini R, Green CJ, Foresti R. Regulation of heme oxygenase-1 by redox signals involving nitric oxide. Antioxid Redox Signal 2002; 4: 615-24.

  7. Valdez LB, Alvarez S, Arnaiz SL, Schopfer F, Carreras MC, Poderoso JJ, Boveris A. Reactions of peroxynitrite in the mitochondrial matrix. Free Radic Biol Med 2000; 29: 349-56.

  8. Pietraforte D, Salzano AM, Marino G, Minetti M. Peroxynitrite- dependent modifications of tyrosine residues in hemoglobin. Formation of tyrosyl radical(s) and 3-nitrotyrosine. Amino Acids 2003; 25: 341-50.

  9. Eiserich JP, Hristova M, Cross CE, Jones AD, Freeman BA, Halliwell B, van der Vliet A. Formation of nitric oxide-derived inflammatory oxidants by myeloperoxidase in neutrophils. Nature 1998; 391: 393-7.

  10. Alvarez B, Radi R. Peroxynitrite reactivity with amino acids and proteins. Amino Acids 2003; 25: 295-311.

  11. Tarpey MM, Wink DA, Grisham MB. Methods for detection of reactive metabolites of oxygen and nitrogen: in vitro and in vivo considerations. Am J Physiol Regul Integr Comp Physiol 2004; 286: R431-R444.

  12. Virag L, Szabo E, Gergely P, Szabo C. Peroxynitrite-induced cytotoxicity: mechanism and opportunities for intervention. Toxicol Lett 2003; 140: 113-24.

  13. Kuzkaya N, Weissmann N, Harrison DG, Dikalov S. Interactions of peroxynitrite with uric acid in the presence of ascorbate and thiols: Implications for uncoupling endothelial nitric oxide synthase. Biochem Pharmacol 2005; 70: 343-54.

  14. Yu H, Liu J, Liu X, Zang T, Luo G, Shen J. Kinetic studies on the glutathione peroxidase activity of selenium-containing glutathione transferase. Comp Biochem Physiol B Biochem Mol Biol 2005; 141: 382-9.

  15. Rajasekaran NS, Sathyanarayanan S, Devaraj NS, Devaraj H. Chronic depletion of glutathione (GSH) and minimal modification of LDL in vivo: its prevention by glutathione mono ester (GME) therapy. Biochim Biophys Acta 2005; 1741: 103-12.

  16. de Haan JB, Stefanovic N, Nikolic-Paterson D, Scurr LL, Croft KD, Mori TA, Hertzog P, Kola I, Atkins RC, Tesch GH. Kidney expression of glutathione peroxidase-1 is not protective against streptozotocin-induced diabetic nephropathy. Am J Physiol Renal Physiol 2005; 289: F544-F551.

  17. Sies H, Sharov VS, Klotz LO, Briviba K. Glutathione peroxidase protects against peroxynitrite mediated oxidations. A new function for selenoproteins as peroxynitrite reductase. J Biol Chem 1997; 272: 27812-17.

  18. Jensen MP, Riley DP. Peroxynitrite decomposition activity of iron porphyrin complexes. Inorg Chem 2002; 41: 4788-97.

  19. Sultana R, Boyd-Kimball D, Poon HF, Cai J, Pierce WM, Klein JB, Markesbery WR, et al. Oxidative modification and down-regulation of Pin1 in Alzheimer’s disease hippocampus: A redox proteomics analysis. Neurobiol Aging 2006, en prensa.

  20. Xie Z, Wei M, Morgan TE, Fabrizio P, Han D, Finch CE, Longo VD. Peroxynitrite mediates neurotoxicity of amyloid betapeptide1-42- and lipopolysaccharide-activated microglia. J Neurosci 2002; 22: 3484-92.

  21. Zhang YJ, Xu YF, Chen XQ, Wang XC, Wang JZ. Nitration and oligomerization of tau induced by peroxynitrite inhibit its microtubule-binding activity. FEBS Lett 2005; 579: 2421-7.

  22. Luth HJ, Munch G, Arendt T. Aberrant expression of NOS isoforms in Alzheimer’s disease is structurally related to nitrotyrosine formation. Brain Res 2002; 953: 135-43.

  23. Browne S, Bowling A, MacGarvey U, Baik M, Berger S, Muqit, M, et al. Oxidative damage and metabolic dysfunction in Huntington’s disease: selective vulnerability of the basal ganglia. Ann Neurol 1997; 41: 646-53.

  24. Pérez-de la Cruz V, González-Cortes C, Galván-Arzate S, Pérez- Severiano F, Ali SF, Pedraza-Chaverri J, Santamaría A. Excitotoxic brain damage involves peroxynitrite-mediated mitochondrial dysfunction, caspase-3 activation and DNA fragmentation in a model of Huntington’s disease in rats: protective role of iron porphyrinate Fe(TPPS). Neuroscience 2005; 135: 463-74.

  25. Ryu JK, Kim SU, McLarnon JG. Blockade of quinolinic acidinduced neurotoxicity by pyruvate is associated with inhibition of glial activation in a model of Huntington’s disease. Exp Neurol 2004; 187: 150-9.

  26. Matthews RT, Yang L, Jenkins BG, Ferrante RJ, Rosen BR, Kaddurah-Daouk R, Beal MF. Neuroprotective effects of creatine and cyclocreatine in animal models of Huntington’s disease. J Neurosci 1998; 18: 156-63.

  27. Galpern WR, Matthews RT, Beal MF, Isacson O. NGF attenuates 3-nitrotyrosine formation in a 3-NP model of Huntington’s disease. Neuroreport 1996; 7: 2639-42.

  28. Thiyagarajan M, Kaul CL, Sharma SS. Neuroprotective efficacy and therapeutic time window of peroxynitrite decomposition catalysts in focal cerebral ischemia in rats. Br J Pharmacol 2004; 142: 899-911.

  29. Imam SZ, Islam F, Itzhak Y, Slikker W Jr, Ali SF. Prevention of dopaminergic neurotoxicity by targeting nitric oxide and peroxynitrite: implications for the prevention of methamphetamine-induced neurotoxic damage. Ann N Y Acad Sci 2000; 914: 157-71.

  30. Onody A, Csonka C, Giricz Z, Ferdinandy P. Hyperlipidemia induced by a cholesterol-rich diet leads to enhanced peroxynitrite formation in rat hearts. Cardiovasc Res 2003; 58: 663-70.

  31. Lancel S, Tissier S, Mordon S, Marechal X, Depontieu F, Scherpereel A, et al. Peroxynitrite decomposition catalysts prevent myocardial dysfunction and inflammation in endotoxemic rats. J Am Coll Cardiol 2004; 43: 2348-58.

  32. Ferdinandy P, Danial H, Ambrus I, Rothery RA, Schulz R. Peroxynitrite is a major contributor to cytokine-induced myocardial contractile failure. Circ Res 2000; 87: 241-7.

  33. Pacher P, Liaudet L, Bai P, Mabley JG, Kaminski PM, Virag L, et al. Potent metalloporphyrin peroxynitrite decomposition catalyst protects against the development of doxorubicin-induced cardiac dysfunction. Circulation 2003; 107: 896-904.

  34. Bianchi C, Wakiyama H, Faro R, Khan T, McCully JD, Levitsky S, Szabo C, Sellke FW. A novel peroxynitrite decomposer catalyst (FP-15) reduces myocardial infarct size in an in vivo peroxynitrite decomposer and acute ischemia-reperfusion in pigs. Ann Thorac Surg 2002; 74: 1201-7.

  35. Pieper GM, Nilakantan V, Chen M, Zhou J, Khanna AK, Henderson JD Jr, et al. Protective mechanisms of a metalloporphyrinic peroxynitrite decomposition catalyst, WW85, in rat cardiac transplants. J Pharmacol Exp Ther 2005; 314: 53-60.

  36. Bitar MS, Wahid S, Mustafa S, Al-Saleh E, Dhaunsi GS, Al-Mulla F. Nitric oxide dynamics and endothelial dysfunction in type II model of genetic diabetes. Eur J Pharmacol 2005; 511: 53-64.

  37. Suarez-Pinzon WL, Szabo C, Rabinovitch A. Development of autoimmune diabetes in NOD mice is associated with the formation of peroxynitrite in pancreatic islet beta-cells. Diabetes 1997; 46: 907-11.

  38. Szabo C, Mabley JG, Moeller SM, Shimanovich R, Pacher P, Virag L, et al. Part I: pathogenetic role of peroxynitrite in the development of diabetes and diabetic vascular complications: studies with FP15, a novel potent peroxynitrite decomposition catalyst. Mol Med 2002; 8: 571-80.

  39. Obrosova IG, Mabley JG, Zsengeller Z, Charniauskaya T, Abatan OI, Groves JT, Szabo C. Role for nitrosative stress in diabetic neuropathy: evidence from studies with a peroxynitrite decomposition catalyst. FASEB J 2005; 19: 401-3.

  40. Li JM, Shah AM. Endothelial cell superoxide generation: regulation and relevance for cardiovascular pathophysiology. Am J Physiol Regul Integr Comp Physiol 2004; 287: R1014-R1030.

  41. Patterson ME, Mouton CR, Mullins JJ, Mitchell KD. Interactive effects of superoxide anion and nitric oxide on blood pressure and renal hemodynamics in transgenic rats with inducible malignant hypertension. Am J Physiol Renal Physiol 2005; 289: F754-F759.

  42. Fortuno A, Jose GS, Moreno MU, Diez J, Zalba G. Oxidative stress and vascular remodelling. Exp Physiol 2005; 90: 457-62.

  43. Li J, Li W, Su J, Liu W, Altura BT, Altura BM. Peroxynitrite induces apoptosis in rat aortic smooth muscle cells: possible relation to vascular diseases. Exp Biol Med 2004; 229: 264-9.

  44. Chang T, Wang R, Wu L. Methylglyoxal-induced nitric oxide and peroxynitrite production in vascular smooth muscle cells. Free Radic Biol Med 2005; 38: 286-93.

  45. Guo W, Adachi T, Matsui R, Xu S, Jiang B, Zou MH, et al. Quantitative assessment of tyrosine nitration of manganese superoxide dismutase in angiotensin II-infused rat kidney. Am J Physiol Heart Circ Physiol 2003; 285: H1396-H1403.

  46. Cuzzocrea S, Mazzon E, Dugo L, Di Paola R, Caputi AP, Salvemini D. Superoxide: a key player in hypertension. FASEB J 2004; 18: 94-101.

  47. Barton CH, Ni Z, Vaziri ND. Enhanced nitric oxide inactivation in aortic coarctation-induced hypertension. Kidney Int 2001; 60: 1083-7.

  48. Ma XL, Gao F, Nelson AH, Lopez BL, Christopher TA, Yue TL, Barone FC. Oxidative inactivation of nitric oxide and endothelial dysfunction in stroke-prone spontaneous hypertensive rats. J Pharmacol Exp Ther 2001; 298: 879-85.

  49. Koksel O, Cinel I, Tamer L, Cinel L, Ozdulger A, Kanik A, Ercan B, Oral U. N-acetylcysteine inhibits peroxynitrite-mediated damage in oleic acid-induced lung injury. Pulm Pharmacol Ther 2004; 17: 263-70.

  50. Naidu BV, Fraga C, Salzman AL, Szabo C, Verrier ED, Mulligan MS. Critical role of reactive nitrogen species in lung ischemia-reperfusion injury. J Heart Lung Transplant 2003; 22: 784-93.

  51. Mabley JG, Liaudet L, Pacher P, Southan GJ, Salzman AL, Szabo C. Part II: beneficial effects of the peroxynitrite decomposition catalyst FP15 in murine models of arthritis and colitis. Mol Med 2002; 8: 581-90.

  52. de Haan JB, Stefanovic N, Nikolic-Paterson D, Scurr LL, Croft KD, Mori TA, et al. Kidney expression of glutathione peroxidase-1 is not protective against streptozotocin-induced diabetic nephropathy. Am J Physiol Renal Physiol 2005; 289: F544-F551.

  53. Modlinger PS, Wilcox CS, Aslam S. Nitric oxide, oxidative stress, and progression of chronic renal failure. Semin Nephrol 2004; 24: 354-65.

  54. Chirino YI, Hernandez-Pando R, Pedraza-Chaverri J. Peroxynitrite decomposition catalyst ameliorates renal damage and protein nitration in cisplatin-induced nephrotoxicity in rats. BMC Pharmacol 2004; 4: 20.

  55. Pedraza-Chaverri J, Barrera D, Maldonado PD, Chirino YI, Macias-Ruvalcaba NA, Medina-Campos ON, et al. S-allylmercaptocysteine scavenges hydroxyl radical and singlet oxygen in vitro and attenuates gentamicin-induced oxidative and nitrosative stress and renal damage in vivo. BMC Clin Pharmacol 2004; 4: 5.

  56. Barrera D, Maldonado PD, Medina-Campos ON, Hernandez-Pando R, Ibarra-Rubio ME, Pedraza-Chaverri J. HO-1 induction attenuates renal damage and oxidative stress induced by K2Cr2O7. Free Radic Biol Med 2003; 34: 1390-8.

  57. Noiri E, Nakao A, Uchida K, Tsukahara H, Ohno M, Fujita T, Brodsky S, Goligorsky MS. Oxidative and nitrosative stress in acute renal ischemia. Am J Physiol Renal Physiol 2001; 281: F948-F957.

  58. Vaziri ND, Ni Z, Oveisi F, Liang K, Pandian R. Enhanced nitric oxide inactivation and protein nitration by reactive oxygen species in renal insufficiency. Hypertension 2002; 39: 135-41.




2020     |     www.medigraphic.com